0808 GMT - DSM-Firmenich will likely communicate on capital returns in advance of further divestment, Jefferies analysts write in a note. The sale of its stake in the Feed Enzymes Alliance to its partner Novonesis brings focus to its balance sheet, the analysts say. "The combination of this divestment and the previously announced Robertet sale represents around 1.8 billion euros of net proceeds from divestment," they add. This suggests that the Dutch nutrition, health and bioscience company could communicate on capital returns even before the finalized remaining Animal Nutrition and Health sale. Shares closed Monday at 95.94 euros. (najat.kantouar@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 03:08 ET (08:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。